Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
VTVT Price Action
Last 7 days
5.2%
Last 30 days
-9.1%
Last 90 days
-23.7%
Trailing 12 Months
-1.6%
VTVT RSI Chart
VTVT Valuation
VTVT Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
VTVT Fundamentals
VTVT Revenue
VTVT Earnings
VTVT Profitability
VTVT Investor Care
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 0 |
| 2024 | 1.0M | 1.0M | 1.0M | 1.0M |
| 2022 | 5.0M | 5.0M | 2.0M | 2.0M |
| 2021 | 5.8M | 5.2M | 4.6M | 4.0M |
| 2020 | 0 | 0 | 0 | 6.4M |
| 2019 | 11.3M | 10.6M | 7.3M | 2.8M |
| 2018 | 2.3M | 4.8M | 8.1M | 12.4M |
| 2017 | 288.0K | 119.0K | 96.0K | 291.0K |
| 2016 | 845.0K | 917.0K | 822.0K | 634.0K |
| 2015 | 1.3M | 1.0M | 776.5K | 519.0K |
| 2014 | 1.1M | 1.3M | 1.4M | 1.5M |
| 2013 | 0 | 0 | 0 | 976.0K |
Get all data in R, Python etc through our Historical Stock Data APIs
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
| CEO | Mr. Paul J. Sekhri M.Sc., MSc |
|---|---|
| WEBSITE | https://vtvtherapeutics.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 13 |
